Exploring Newer Nonsteroidal Topical Treatments for Atopic Dermatitis: JAK Inhibitors and AhR Agonists
Panelists discuss how roflumilast demonstrated good efficacy with 56% to 57% of patients achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 after long-term use, making it effective for maintenance therapy with good tolerability.
Video content above is prompted by the following:
Topical Janus kinase (JAK) Inhibitors in Atopic Dermatitis Management
Agents Discussed: Ruxolitinib (Opzelura), Tapinarof
Ruxolitinib (Topical JAK1/JAK2 Inhibitor)
- Indication and Approval:
- Approved for the treatment of atopic dermatitis in patients aged 12 years and older
- Maximum recommended body surface area (BSA) coverage is 20%, per FDA labeling
- Efficacy Data:
- In the TRuE-AD1 study, 54% of patients using 1.5% ruxolitinib cream achieved an IGA score of 0 or 1 (clear or almost clear skin)
- Demonstrated superiority to medium-potency topical steroids (triamcinolone 0.1% ointment) in a phase 2 head-to-head study, with greater efficacy in reducing inflammation and pruritus
- Tolerability and Safety:
- Common adverse events include nasopharyngitis, upper respiratory tract infections, and headache.
- Notable for lack of local adverse effects often associated with corticosteroids, such as atrophy, striae, and hypopigmentation—a key benefit in treating sensitive areas (eg, face, genitals, intertriginous zones)
- Black Box Warning:
- Important to contextualize: The black box warning stems from a phase 4 safety trial of oral JAK inhibitors (tofacitinib) in older patients with rheumatoid arthritis, where increased risks of thromboembolism and cardiovascular events were observed
- These findings do not directly apply to topical formulations, which have minimal systemic absorption, yet the warning remains due to the class effect
- Physicians should educate patients and caregivers about this distinction to mitigate concerns
Tapinarof (Topical Aryl Hydrocarbon Receptor [Ahr] Modulator)
- Study Reference: ADORING Clinical Trial:
- Included 813 subjects, 18 years or younger, with an average BSA involvement of approximately 17%
- Efficacy:
- After 8 weeks of treatment, approximately 45% to 46% of participants achieved an IGA score of 0 or 1.
- Adverse Events:
- Most common: Folliculitis, headache, and nasopharyngitis
- Folliculitis appears to be the most prominent adverse event in clinical practice
- Management includes standard treatments such as topical clindamycin or benzoyl peroxide washes
- Clinical Considerations:
- Generally, well tolerated
- A nonsteroidal alternative beneficial for patients seeking long-term topical treatment without corticosteroid-associated risks
Clinical Takeaways
- Topical JAK inhibitors like ruxolitinib offer effective nonsteroidal alternatives with notable benefits in itch relief, inflammation reduction, and safety profile, especially in sensitive or chronic-use areas
- Physicians should educate patients on the context of black box warnings, and tailor therapy based on efficacy, tolerability, and anatomical site of involvement
- Tapinarof presents another promising nonsteroidal option, with mild, manageable adverse effects
Recent Videos
Related Content
